eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
abstract:
Review paper

NEWLY-EMERGING SIDE EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE USAGE ASSOCIATED WITH WEIGHT LOSS TREATMENT

Paula Bieganek
1
,
Bartosz Sadłowski
1
,
Stanisław Łukaszewicz
1
,
Piotr Pawłowski
2
,
Julia Rybak
3
,
Jakub Kordialik
4
,
Julia Koćwin
1
,
Sandra Sarnacka
5
,
Michał Tokarski
6
,
Angelika Banasiak
7

  1. Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz, Central Veteran Hospital, Lodz, Poland
  2. S. Zeromski Specialist Hospital, Cracow, Poland
  3. Faculty of Medicine, Medical College, Jagiellonian University, Cracow, Poland
  4. Karol Jonscher Municipal Medical Center, Lodz, Poland
  5. Mikolaj Pirogow Provincial Specialist Hospital, Lodz, Poland
  6. Maria Skłodowska-Curie Specialist Hospital, Brzeziny, Poland
  7. Nicolaus Copernicus Specialist Hospital, Lodz, Poland
Health Prob Civil.
DOI: https://doi.org/10.5114/hpc.2024.140505
Online publish date: 2024/06/13
View full text Get citation
 
PlumX metrics:
GLP-1 agonists, such as semaglutide and liraglutide, are some of the most promising drugs in therapy for treating obesity in patients with type 2 diabetes as well as patients without diabetes. With many positive effects, not only in treating obesity but also in positively affecting blood glucose levels, blood pressure and cardiac muscle, they are among the most commonly used drugs in the general practitioner’s office. However, with the increasing popularity of drugs such as semaglutide and liraglutide, questions about the safety of using these medications are also on the rise. It is widely known that drugs such as semaglutide act on receptors GLP-1 and delay gastric emptying, which in the longer time period can lead to gastroparesis. Additionally, patients may experience rapid loss of facial fat due to quick weight loss, leading to a condition known as ‘Ozempic face’. Acute pancreatitis may occur in patients using semaglutide or liraglutide due to the presence of GLP-1 receptors on the pancreatic islets, which can cause hyperplasia and inflammation during the use of these drugs.
keywords:

semaglutide, gastroparesis, liraglutide, pancreatitis, obesity

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.